|Bid||3.6600 x 900|
|Ask||3.6700 x 4000|
|Day's Range||3.5500 - 3.9475|
|52 Week Range||3.5500 - 18.5000|
|Beta (3Y Monthly)||2.65|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2019 - Aug 12, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||12.08|
Paul Campanelli became the CEO of Endo International plc (NASDAQ:ENDP) in 2016. This report will, first, examine the...
In 2016 Paul Campanelli was appointed CEO of Endo International plc (NASDAQ:ENDP). This report will, first, examine...
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
BRIDGEWATER, N.J. and RALEIGH, N.C., June 18, 2019 -- Nevakar Inc. (“Nevakar” or the “Company”), a specialty pharmaceutical company developing multiple assets in the ophthalmic.
Endo International PLC NASDAQ/NGS:ENDPView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for ENDP with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ENDP totaled $9.50 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Ask About the Curve raises awareness of Peyronie's disease, a men's health condition that may affect about 1 in 10 men and leads to a pronounced curvature in the penis and potential pain during arousal. Endo Pharmaceuticals and Dr. Spitz encourage men to conduct self-penile exams to look for a curvature and feel for a lump this June, which is Men's Health Month.
DUBLIN , May 17, 2019 /CNW/ -- Endo International plc (ENDP) today announced that clinical data from a Phase 3 investigational study of collagenase clostridium histolyticum (CCH) for the treatment of cellulite will be presented by Lawrence Bass , M.D., a board-certified plastic surgeon with a practice in New York City . Dr. Bass will present the Phase 3 data during the Premier Global Hot Topics session, which takes place today from 1:00pm – 6:00pm (Central Time) at the New Orleans Ernest N. Morial Convention Center. The Hot Topics session is considered to be a highlight of The Aesthetic Meeting 2019, the annual meeting of the American Society for Aesthetic Plastic Surgery (The Aesthetic Society).
Some stocks are best avoided. We really hate to see fellow investors lose their hard-earned money. Imagine if you held...
Teva or Endo: Which Is the Better Pick in May?(Continued from Prior Part)First-quarter performanceIn the first quarter, Endo International (ENDP) reported revenue of $720.41 million, a YoY (year-over-year) rise of 2.84% and $28.10 million higher
DUBLIN , May 15, 2019 /PRNewswire/ -- Endo International plc (NASDAQ: ENDP) announced today that members of management will participate in a fireside chat at the RBC Annual Healthcare Conference in New ...
Endo (ENDP) delivered earnings and revenue surprises of 26.19% and 4.07%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Dublin-based company said it had a loss of 8 cents per share. Earnings, adjusted for non-recurring costs and to account for discontinued operations, came to 53 cents per share. The results exceeded ...
Drugmaker Endo International Plc reported a smaller quarterly loss on Thursday, as sales of its sterile injectables and branded drugs rose. Net loss narrowed to $18.6 million, or 8 cents per share, for ...
(Reuters) - Drugmaker Endo International Plc reported a first-quarter profit that beat analysts' estimates on Thursday, helped by growing sales of its drug Xiaflex and higher revenue at its sterile injectables ...
CNBC's "Power Lunch" team discusses generic drug makers' price fixing allegations with Chester "Chip" Davis, CEO of the Association of Accessible Medicines.